首页> 外文期刊>Journal of Pharmaceutical Health Care and Sciences >Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
【24h】

Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1

机译:口服抗癌药物S-1的患者眼泪量和眼部症状的变化

获取原文
           

摘要

Background Most eye disorders are not fatal but may deteriorate the quality of life of a patient. The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). However, preventive methods or treatment methods for the eye disorder have not yet been established. This study aimed to determine changes in tear volume and subjective ocular symptoms during the treatment period in patients receiving S-1 monotherapy for early detection of adverse effects in the eye and establishment of its treatment methods. Methods This study included eleven patients receiving S-1 monotherapy as a postoperative adjuvant chemotherapy for gastric cancer. Six subjective ocular symptoms including watering eyes were evaluated and changes in tear volume measured by the Schirmer’s test in patients receiving S-1 during the treatment period. In the present study, the patients were divided into “no watering eyes” (patients not experienced watering eyes) group and “watering eyes” (patients experienced watering eyes even once) group. Results Six out of eleven patients developed watering eyes after receiving S-1 monotherapy. Among these, the earliest onset occurred on the 2nd week after oral administration. Watering eyes and eye discharge were highly related in patients having a trouble in daily life due to the decreased QOL. Changes in tear volume in the “watering eyes” group significantly increased compared to the “no watering eyes” group during the treatment period, especially when the patients had no subjective symptom of the increased tear volume. Conclusions It is essential to prevent eye disorders including watering eyes as an adverse effect of S-1 administration. The present study recommends that the tear volume should be periodically measured using Schirmer’s test, and the patient should be interviewed regarding the subjective ocular symptoms for the early detection of watering eyes caused by S-1 administration. If the tear volume can not be measured periodically, medical staffs should pay attention to the patient with eye discharge.
机译:背景技术大多数眼疾并非致命,但可能会恶化患者的生活质量。在癌症化学疗法中最常报告的眼部疾病与替加福/吉美拉西/奥沙酸钾(S-1)的组合有关。然而,尚未建立针对眼疾的预防方法或治疗方法。这项研究旨在确定接受S-1单药治疗的患者在治疗期间的眼泪量和主观眼部症状的变化,以早期发现眼睛的不良反应并建立治疗方法。方法该研究包括11例接受S-1单一疗法作为胃癌术后辅助化疗的患者。在治疗期间,对接受S-1治疗的患者进行了包括流眼水在内的六种主观眼部症状评估,并通过Schirmer检验测量了泪液量的变化。在本研究中,将患者分为“无水眼”(无水眼的患者)组和“水眼”(甚至有水眼的患者)组。结果11名患者中有6名在接受S-1单药治疗后出现了流眼水。其中最早的发作发生在口服后第二周。由于QOL降低而在日常生活中出现问题的患者,眼睛浇水和眼球出射高度相关。与“无流眼”组相比,在治疗期间,“流眼”组的眼泪量变化明显增加,尤其是当患者没有主观症状的眼泪量增加时。结论预防眼睛不适,包括流眼水是S-1给药的不良反应。本研究建议应使用Schirmer检验定期测量泪液量,并应就主观眼部症状与患者进行面谈,以及早发现由S-1给药引起的流眼水。如果无法定期测量眼泪量,医务人员应注意带眼出院的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号